3 ms·
> So two of 12 died.. > Another three has significant neutropenia. I’m not claiming this company is or is not ethical, or that this treatment is or is not saf
by Someone 1y ago
> So two of 12 died..
> Another three has significant neutropenia.
I’m not claiming this company is or is not ethical, or that this treatment is or is not safe, but the existing treatment for diabetes type 1 is annoying for patients, but works well.
Because of that, you can’t, ethically, do phase 1 trials on patients that have both a long life expectancy and for which that treatment is an option.
That, in turn, means it isn’t uncommon for patients to die from causes unrelated to the treatment during clinical trials.
As an example, the subject in an earlier study on this kind of treatment (possibly/likely the same medicine; https://diabetesjournals.org/diabetes/article/71/Supplement_1/259-OR/145478/259-OR-Stem-Cell-Derived-Fully-Differentiated https://diabetesjournals.org/diabetes/article/71/Supplement_...) was “A 64-year-old male with a 40-year history of T1D complicated by impaired awareness of hypoglycemia with 5 severe hypoglycemic events (SHEs) the year before”.